Last reviewed · How we verify
NCT01896388
Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial
Phase 1/Phase 2 trial testing Ifenprodil Tartrate in Posttraumatic Stress Disorders in 10 participants. Completed in 1 March 2019.
1 March 2019
Quick facts
| Lead sponsor | Chiba University |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 21 January 2014 |
| Primary completion | 1 March 2019 |
| Estimated completion | 1 March 2019 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Ifenprodil Tartrate — full drug profile →
- Placebo
Conditions studied
- Posttraumatic Stress Disorders — all drugs for Posttraumatic Stress Disorders →
Sponsor
Chiba University
Who can join
Adults 13 to 18, any sex, with Posttraumatic Stress Disorders. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The Impact of Event Scale-Revised Japanese Version : IES-R-J
Time frame: Changes from baseline in IES-R-J at 4-weeks
Evidence includes retest reliability and internal consistency of the IES-R-J. Posttraumatic stress disorder (PTSD) and partial PTSD cases indicated significantly higher scores than non-PTSD cases. The IES-R-J can be a useful self-rating diagnostic instrument particularly for survivors with PTSD symptoms as a clinical concern (PTSD + partial PTSD) by using a 24/25 cutoff in total score. The IES-R-J
Sponsor's own description
Accumulating evidence suggests a key role of the N-methyl-D-aspartate (NMDA) receptor in the pathophysiology of post-traumatic stress disorder (PTSD). Recent studies suggest that the NMDA receptor antagonist ifenprodil tartrate may be a potential therapeutic drug for PTSD. The purpose of this study is to confirm whether ifenprodil tartrate is effective in the treatment of adolescents PTSD patients. If ifenprodil tartrate is effective in these patients, this study contributes to the development of novel therapeutic drugs for PTSD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.
Knezevic NN, Yekkirala A, Yaksh TL. · · 2017 · cited 24× · PMID 29049116 · DOI 10.1213/ane.0000000000002442
Verify or expand the search:
- PubMed search for NCT01896388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chiba University trials
Trials by the same sponsor.
- NCT06611696 — Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis · Phase 4 · recruiting
- NCT03186040 — Open-label Clinical Trial of Lacosamide in ALS · Phase 1, PHASE2 · completed
- NCT02770794 — Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01896388 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chiba University
- Last refreshed: 17 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01896388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing